Should You Buy the iShares S&P 500 ETF Before 2026, Even With the Stock Market at an All-Time High?

The piece highlights the S&P 500’s long-run compound annual return of 10.5% since 1957 and notes the index’s current outperformance driven by a concentrated technology weighting (information technology ~34.5%), with Nvidia, Microsoft and Apple together valued at roughly $12.2 trillion. It recommends the low-cost iShares Core S&P 500 ETF (IVV; 0.03% expense ratio) as a broad, diversified vehicle while warning valuations are elevated and advocating a multi-year horizon and dollar-cost averaging; sector weightings cited include Financials 13.44%, Consumer Discretionary 10.55%, Communication Services 10.50%, Healthcare 9.52% and Industrials 8.18%.

Analysis

Market structure: The S&P’s rally is narrowly driven — roughly one dozen mega-cap tech names (NVDA, MSFT, AAPL, AVGO, AMD) are delivering disproportionate returns, concentrating passive-cap flows and increasing market-cap weighting risk. Winners: AI-processor designers and cloud operators (NVDA, AVGO, MSFT) capture pricing power and margin expansion; losers: mid-/small-cap cyclicals and value sectors will underperform if flows remain tech-centric. This concentration raises tail volatility: ETF outflows from IVV/VOO during a drawdown would disproportionately punish liquidity in the largest names.

Risk assessment: Key tail risks are (1) US/EU export controls or Chinese restrictions on AI chip flows within 3–12 months, (2) geopolitical disruption to Taiwan semiconductor supply within 1–5 years, and (3) a macro shock that re-prices growth vs rates. Short-term (days–weeks) momentum dominates price action; medium-term (earnings over next 1–6 months) decides guidance; long-term (2–5 years) depends on capex cycles and AI revenue realization. Hidden dependency: passive inflows amplify volatility and create feedback loops around a handful of tickers.

Trade implications: Tactical direct longs: NVDA and AVGO for 6–12 months (expect asymmetric upside if AI adoption sustains); hedge with 3–6 month OTM puts sized 2–4% of portfolio to cap tail risk. Relative trades: pair long NVDA vs short IWM (equal dollar) to express concentration bet; use call spreads to limit premium. Cross-asset: rising tech valuations increase sensitivity to 2s–10s moves — buy curve-flattening protection if Fed surprises on rates.

Contrarian angles: Consensus underestimates systemic ETF concentration risk and overestimates durable margin gains for all tech—AI monetization is uneven (hardware wins more than some software incumbents). History: late-1990s tech concentration reversed violently once earnings/growth missed guidance; this cycle differs because of tangible AI demand, but valuation multiples are high and mean-reversion risk remains material. Unintended consequence: large passive ownership may force liquidity-driven selling in stress, creating entry opportunities if one is capitalized.

Key Decisions for Investors

• Establish a 1.5–3% net long position in NVDA (ticker NVDA) over 2–4 weeks; hedge with 3–6 month 10% OTM puts sized at 25% of the equity position to limit downside. Rationale: highest AI exposure; target +30–50% over 6–12 months; trim 30% on a 25% rally and stop-loss -12% from entry.
• Initiate a dollar-cost-averaging plan into IVV (iShares Core S&P 500) allocating 2% of portfolio over 6 months (0.33% per month) to control entry at all-time highs while maintaining long-term exposure. Tear-down trigger: if S&P 500 forward P/E expands >10% from current, pause new buys and reassess fundamentals.
• Execute a pair trade: long AVGO 1–2% vs short IWM (Russell 2000 ETF) 1–2% equal-dollar to play AI/semiconductor pricing power vs small-cap lag. Time horizon 3–9 months; close if AVGO underperforms IWM by 10% or AVGO rallies >30%.
• Implement portfolio tail hedge: buy 3–6 month IVV/SPY 7–12% OTM put protection sized to 3–5% of portfolio to protect against a 15–25% market drawdown tied to a de-risking in mega-cap tech. Adjust hedge if geopolitical/export-control headlines occur within a 30–90 day window (reduce NVDA/AVGO exposure by 25% if formal export restrictions announced).